drugset / Trial / NCT04042727

Controlling Rapid Atrial Fibrillation With Dexmedetomidine

NCT04042727

Phase 2/3 Terminated 13 enrolled Stony Brook University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the effects of Dexmedetomidine (DEX), on heart rate control in patients with rapid atrial fibrillation (AF) through a pragmatic, randomized, double blinded study comparing the addition of Dex or placebo to standard of care (SOC) treatment.

Timeline

Start
2019-08-21
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1 ug/kg Intravenous

Indications